Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GLAUKOS CorpGKOS · Entity 3510 | Director | July 31, 2026 | August 03, 2026 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GLAUKOS Corp
Report date July 31, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,092 |
Reported balance
After 2026-07-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-31 · Sale · Disposed 525 · Balance 21,092 F1: Includes 2,501 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,501 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person.
UroGen Pharma Ltd.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right ot buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.99 · Expires 2036-06-22 | Direct | 10,000 |
Reported balance
After 2026-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 8,000 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 8,000 · Balance 8,000 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F3: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 3, 2026 20:41 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 525 | $167.63 | $88,005.75 |
DisclosureSEC source: 0001847598-26-000010 · form4-08032026_080848.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,092 F1 · balance_after: Includes 2,501 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 13:58 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-021511 · rdgdoc.xml · derivative · entry 2 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. F3 · derivative.expiration_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 13:58 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right ot buy) · Derivative | 10,000 | $0.00 Strike: $34.99 | $0.00 |
DisclosureSEC source: 0001437749-26-021511 · rdgdoc.xml · derivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2036-06-22 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 22:21 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 2,987 | $0.00 Strike: $53.57 | $0.00 |
DisclosureSEC source: 0001847598-26-000006 · form4-06012026_100644.xml · derivative · entry 2 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,987 Underlying: Common Stock · 2,987 shares Expires 2036-05-28 F3 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 22:21 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001847598-26-000006 · form4-06012026_100644.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,617 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 4,609 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| May 28, 2026 Filed Jun 23, 2026 23:27 UTC Amendment | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 2,987 | $0.00 Strike: $106.52 | $0.00 |
DisclosureSEC source: 0001847598-26-000008 · form4a-06232026_110643.xml · derivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,987 Underlying: Common Stock · 2,987 shares Expires 2036-05-28 F1 · derivative.exercise_price: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. F2 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 01, 2026 Filed May 4, 2026 22:07 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 1,700 | $143.35 | $243,695.00 |
DisclosureSEC source: 0001847598-26-000004 · form4-05042026_100551.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,739 F1 · balance_after: Includes 2,731 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| January 02, 2026 Filed Jan 8, 2026 00:18 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 623 | $0.00 | $0.00 |
DisclosureSEC source: 0001847598-26-000002 · form4-01082026_120121.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,439 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 2,731 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:46 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Unit · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-036557 · rdgdoc.xml · derivative · entry 2 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:46 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionordinary shares | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-036557 · rdgdoc.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 20:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-027878 · rdgdoc.xml · derivative · entry 2 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. F3 · derivative.expiration_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 20:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right ot buy) · Derivative | 10,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001437749-25-027878 · rdgdoc.xml · derivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2035-08-26 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 3,149 | $0.00 Strike: $94.87 | $0.00 |
DisclosureSEC source: 0001415889-25-015160 · form4-06022025_080653.xml · derivative · entry 3 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,149 Underlying: Common Stock · 3,149 shares Expires 2035-05-29 F5 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of the grant date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015160 · form4-06022025_080653.xml · nonDerivative · entry 2 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,816 F3 · security: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F4 · balance_after: Includes 4,285 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| January 02, 2025 Filed Jun 2, 2025 20:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 461 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015160 · form4-06022025_080653.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,708 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 2,177 restricted stock units that have not yet vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 13:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right ot buy) · Derivative | 10,000 | $0.00 Strike: $15.16 | $0.00 |
DisclosureSEC source: 0001437749-24-025292 · rdgdoc.xml · derivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2034-08-06 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 00:56 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 1,246 | $0.00 Strike: $110.70 | $0.00 |
DisclosureSEC source: 0001415889-24-015238 · form4-06042024_120653.xml · derivative · entry 2 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,246 Underlying: Common Stock · 1,246 shares Expires 2034-05-30 F3 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of the grant date. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 00:56 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015238 · form4-06042024_120653.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,247 F1 · security: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of 4,946 restricted stock units that have not yet vested or have not been delivered to the Reporting Person. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 19:41 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right ot buy) · Derivative | 10,000 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001437749-23-025480 · rdgdoc.xml · derivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2033-09-07 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 00:15 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009297 · form4-06062023_120643.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,531 F1 · security: Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of restricted stock units that have not yet vested or have not been delivered to the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:21 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000444 · form4-01042023_110104.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,301 F1 · security: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:16 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000440 · form4-01042023_110127.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,301 F1 · security: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 7,990 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 12:28 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001437749-22-022162 · rdgdoc.xml · derivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2032-09-08 F1 · derivative.exercise_date: The shares underlying the stock option vest in equal quarterly installments for 12 quarters Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 23:57 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 4,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-068670 · tm2217841-7_4seq1.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,729 F1 · security: Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of 10,254 restricted stock units that have not yet vested or been delivered to the Reporting Person, and 1,475 restricted stock units that have vested but have not yet been delivered to the Reporting Person based upon the Reporting Person's election to defer delivery. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:59 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-001666 · tm221974-6_4seq1.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 6,916 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 22:47 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-077830 · tm2119039-4_4seq1.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,910 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 5,461 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:03 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 449 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-031667 · tm218619-4_4seq1.xml · nonDerivative · entry 2 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,528 F3 · security: Represents a grant of restricted stock units received by the reporting person as the prorated portion of the annual equity grant upon appointment to the Issuer's Board of Directors pursuant to the Issuer's Director Compensation Policy. These restricted stock units vest on June 3, 2021. F2 · balance_after: Consists of restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:03 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 3,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-031667 · tm218619-4_4seq1.xml · nonDerivative · entry 1 WEN LEANA · CIK 0001847598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,079 F1 · security: Represents a grant of restricted stock units received by the reporting person as an initial equity grant upon appointment to the Issuer's Board of Directors, pursuant to the Issuer's Director Compensation Policy. One-third of the restricted stock units vest on each of the first three anniversaries of the grant date, and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.